한빛사
>
한빛사논문
한빛사논문
- 조회520
Exp. Mol. Med., Sep 01 2023, | https://doi.org/10.1038/s12276-023-01080-3
Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment.
Juwon Yang 1 and Hyunsu Bae 1,*
1Department of Korean Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
*Corresponding author: correspondence to Hyunsu Bae
Abstract
Within the tumor microenvironment (TME), regulatory T cells (Tregs) play a key role in suppressing anticancer immune responses; therefore, various strategies targeting Tregs are becoming important for tumor therapy. To prevent the side effects of nonspecific Treg depletion, such as immunotherapy-related adverse events (irAEs), therapeutic strategies that specifically target Tregs in the TME are being investigated. Tumor-targeting drug conjugates are efficient drugs in which a cytotoxic payload is assembled into a carrier that binds Tregs via a linker. By allowing the drug to act selectively on target cells, this approach has the advantage of increasing the therapeutic effect and minimizing the side effects of immunotherapy. Antibody-drug conjugates, immunotoxins, peptide-drug conjugates, and small interfering RNA conjugates are being developed as Treg-targeting drug conjugates. In this review, we discuss key themes and recent advances in drug conjugates targeting Tregs in the TME, as well as future design strategies for successful use of drug conjugates for Treg targeting in immunotherapy.
논문정보
- Review Paper
- 2023년 09월 (BRIC 등록일 2023-09-08)
- 국내 연구진
- 생명과학 > 면역학
댓글 작성 로그인
팝업 닫기관련 링크
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
